Raymond James raised the firm’s price target on Tenet Healthcare to $175 from $130 and keeps a Strong Buy rating on the shares. Tenet’s Q2 results were relatively in-line with expectations after adjusting out the $30M out of period supplemental payment revenue from Texas, and $5M of grant income, the analyst tells investors in a research note. Fundamentals are driving the story with more road to go, the firm argues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare raises FY24 adjusted EPS view to $10.41-$11.12 from $8.37-$9.41
- Tenet Healthcare sees Q3 adjusted EPS $2.16-$2.58
- Tenet Healthcare announces new $1.5B share repurchase program
- Tenet Healthcare reports Q2 adjusted EPS $2.31 vs. $1.44 last year
- THC Earnings this Week: How Will it Perform?